The week in pharma: action, reaction and insight - week to December 10, 2021

12 December 2021

By Barbara Obstoj-Cardwell

Regulatory news featured last week, with US drugmaker AbbVie announcing that the US Food and Drug Administration is now requiring its Rinvoq to carry a Boxed Warning, following the agency’s identification of safety issues with the JAK inhibitor class of drugs for rheumatoid arthritis. Also, US biotech Reata Pharmaceuticals suffered a setback last Wednesday, when an FDA advisory committee voted against approval of bardoxolone for Alport-caused kidney disease. On the deal-making front, Ionis entered into an agreement with the UK’s AstraZeneca to develop its rare disease drug eplontersen, that could earn the company $3.6 billion. Neurocrine Biosciences last Tuesday released Phase III data showing positive results for its Huntington disease candidate Ingrezza.

Rinvoq gets updated Boxed Warning

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK